The National Alliance on Mental Illness (NAMI) is providing a new dimension to its Hearts & Minds initiative, an educational program that promotes "mind and body" health practices for individuals who live with mental illness...

Forest Laboratories, Inc. (NYSE: FRX) and Gedeon Richter Plc. today announced preliminary top-line results from an 8-week Phase II clinical trial of the novel, investigational antipsychotic agent cariprazine for the treatment of bipolar depression. Cariprazine is currently undergoing Phase III trials for separate indications of schizophrenia and bipolar mania...

Schizophrenia and related psychotic disorders are a chronic and often disabling condition. Despite modern treatment techniques they still present an enormous burden to the patients and their relatives and take a serious toll in terms of human suffering and societal expenditure...

The incidence of psychotic disorders varies greatly across places and demographic groups, as do symptoms, course, and treatment response across individuals. High rates of schizophrenia in large cities, and among immigrants, cannabis users, and traumatised individuals reflect the causal influence of environmental exposures...

An international study led by University of Montreal scientists suggests family history may not be a good predictor of the presence of mutations predisposing to autism or schizophrenia. The findings show how new or de novo gene mutations - alterations of the cell's DNA - play a role in these devastating conditions...

NICE is currently developing a clinical guideline on the assessment and management of psychosis with co-existing substance misuse in adults and young people. As part of this process, draft recommendations have been published on the NICE website for public consultation...

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, after peaking at $6.3 billion in 2011, the schizophrenia drug market will decline to $5.2 billion in 2019, owing to the loss of patent protection for most atypical antipsychotics on the market...

It has been nearly a century since the term "schizophrenia" was first used to describe what was then considered a hopeless and incurable disorder of thought and emotion. Schizophrenia is still baffling to both scientists and the general public, but it is no longer considered hopeless...

Infections like the flu are common occurrences during pregnancy, and research has shown that children born to mothers who suffered from flu, viruses and other infections during pregnancy have about a 1.5 to 7 times increased risk for schizophrenia. A new study out of Temple University examines what's behind that link...

A group of scientists has identified a genetic variant that substantially increases the risk for developing schizophrenia in Ashkenazi Jewish and other populations. The study, published by Cell Press on August 5th in the American Journal of Human Genetics, associates a deletion on chromosome 3 with increased incidence of schizophrenia...

A commonplace electroencephalography (EEG) test may hold the key to predicting whether a person will respond to certain prescribed drugs, particularly those related to psychiatric conditions...

The six-site Consortium on the Genetics of Schizophrenia (COGS), led by the director of the Schizophrenia Program at the University of California, San Diego School of Medicine, has received a $10 million renewal grant from the National Institute of Mental Health (NIMH), one of the National Institutes of Health...

Intra-Cellular Therapies, Inc. announced the results from a Phase Ib/II clinical trial in patients with schizophrenia with ITI-007, the Company's unique, investigational new drug for the treatment of schizophrenia. The trial met its primary endpoint demonstrating that ITI-007 was safe and well-tolerated in patients with stabilized schizophrenia...

About 1 in 10 people have the potential to develop schizophrenia, but only 1 in 100 actually end up with this devastating illness. The challenge is in knowing why some do and some don't. Drawing from over 25 years of laboratory study, Mark F...

People with schizophrenia are more likely than others to sustain medical injuries during non-psychiatric hospital stays, a large national study finds...

Scientists are making progress towards a better understanding of the neuropathology associated with debilitating psychiatric illnesses like bipolar disorder and schizophrenia. New research, published by Cell Press in the July 15 issue of the journal Neuron, reveals mechanisms that connect a known psychiatric risk gene to disruptions in brain cell proliferation and migration during development...

Researchers at the University of Granada have designed a new training program on specific self-efficacy for reducing stress in psychotic patients. When stress was reduced, patients reported an improvement in symptoms, which meant enhancement of their well-being and quality of life. Researchers proved that these patients can improve their quality of life through proper psychological intervention...

People with mental health problems are committing fewer homicides while the number of suicides by mental health patients has also fallen, latest figures reveal; a previous rise in homicides by mentally ill people may have been the result of drug misuse, says the report...

Learning and memory impairments are important contributors to the disability associated with schizophrenia. These functional impairments emerge long before the onset of other symptoms associated with schizophrenia, suggesting that they are a consequence of a disturbance in brain development...

Dendritic spines act as hubs for communication between nerve cells. Reductions in spines may contribute to a lack of coordination in activity between brain regions. This structural abnormality is particularly relevant in schizophrenia, where pyramidal neurons located in layer 3, the principal cell type receiving communication from other brain regions, have fewer dendritic spines...